Synonyms: MK7622
Compound class:
Synthetic organic
Comment: MK-7622 is a high cooperativity positive allosteric modulator of the M1 muscarinic acetylcholine receptor (M1R) [1-3]. Clinical development of MK-7622 as a therapy for neurological and cognitive disorders was terminated at Phase 2.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Beshore DC, N Di Marco C, Chang RK, Greshock TJ, Ma L, Wittmann M, Seager MA, Koeplinger KA, Thompson CD, Fuerst J et al.. (2018)
MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate. ACS Med Chem Lett, 9 (7): 652-656. [PMID:30034595] |
2. Mandai T, Sako Y, Kurimoto E, Shimizu Y, Nakamura M, Fushimi M, Maeda R, Miyamoto M, Kimura H. (2020)
T-495, a novel low cooperative M1 receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk. Pharmacol Res Perspect, 8 (1): e00560. DOI: 10.1002/prp2.560 [PMID:31990455] |
3. Uslaner JM, Kuduk SD, Wittmann M, Lange HS, Fox SV, Min C, Pajkovic N, Harris D, Cilissen C, Mahon C et al.. (2018)
Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622. J Pharmacol Exp Ther, 365 (3): 556-566. [PMID:29563325] |
4. Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M et al.. (2018)
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimers Dement (N Y), 4: 173-181. [PMID:29955661] |